87 - Opioid Dependence and Non-Canonical Targets for Medication Development

Session Chair(s)

• Rita Valentino

  NIH

• Jill Turner

  University of Kentucky

Opioid use disorder (OUD) is a leading cause of morbidity and mortality in the United States. Yet, very few therapeutic options are available to individuals suffering from opioid use disorder, indicating novel drug development for OUD is critically needed. This panel, chaired by Dr. Jill Turner, the 2021 Division for Neuropharmacology Early Career Awardee, will discuss new and exciting directions in medication development for this debilitating disorder, centered on modulating neuroinflammatory responses to opioid exposure and withdrawal.

Presentations:

• 8:00 AM – 8:05 AM

  Introduction
• 8:05 AM – 8:25 AM

  Peripheral-Central Immune Crosstalk and Affective Dysruption Salient to OUD
  

  Speaker: Georgia Hodes – Virginia Tech
• 8:25 AM – 8:35 AM

  Cell-type Specific Transcriptome and Genome Alterations in OUD
  

  Speaker: Lilian Goncalves Custodio – University of Kentucky
• 8:35 AM – 8:55 AM

  New Approaches to Therapeutic Delivery for OUD
  

  Speaker: Fair Vassoler – Cummings School of Veterinary Medicine at Tufts University
• 8:55 AM – 9:05 AM

  Multivalent Vaccine Strategies against Polydrug Use in Opioid Use Disorders
  

  Presenting Author: Daihyun Song – University of Minnesota
• 9:05 AM – 9:30 AM

  Panel Conclusion and Muddiest Point